dibotermin alpha
Trade name: inductos
Small moleculeexperimental
Clinical trial activity
6 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Sep 1, 2003 (NCT00161616)
Timeline
Indications
Approved for
Mechanism of action
- Bone morphogenetic protein 2Supplementation
BMP2 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- inductos
- inductos
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05911477 | N/A | Jul 1, 2023 | Xijing Hospital |
| NCT05717478 | N/A | Nov 15, 2022 | Universidad Complutense de Madrid |
| NCT05238740 | N/A | Oct 27, 2022 | Lindenhof AG, University of Bern |
| NCT05719181 | Phase 1 | Dec 6, 2021 | University of Baghdad |
| NCT01541345 | Phase 3 | Feb 1, 2011 | University of Zurich |
| NCT00161616 | Phase 4 | Sep 1, 2003 | Pfizer, Wyeth |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lindenhof AG | For profit | 1 | 1 | 1 | 2022 |
| Pfizer | For profit | 1 | 1 | 1 | 2003 |
| Universidad Complutense de Madrid | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Baghdad | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Zurich | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Wyeth | For profit | 1 | 0 | 1 | 2003 |
| Xijing Hospital | Academic/Hospital | 1 | 1 | 1 | 2023 |
8 organizations
Page 1 / 1